Get the Stockscreener App
2.15
1.90%
0.04
Innate Pharma Adr Stock (IPHA) Forecast
The Innate Pharma Adr (IPHA) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $1.4503, representing a -32.55% decrease from the current price of $2.15. The highest analyst price target is $1.9171, and the lowest is $0.9834.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month IPHA Price Target
Average 4.7238
(+119.71% Upside)
Is Innate Pharma Adr (IPHA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 63.50 | Neutral |
| STOCH(9,6) | 53.38 | Neutral |
| STOCHRSI(14) | 79.71 | Neutral |
| MACD(12,26) | 0.0649 | Buy |
| ADX(14) | 40.68 | Buy |
| William %R | -52.17 | Neutral |
| CCI(14) | 66.71 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.0553
Buy
|
2.0571
Buy
|
| MA20 |
1.9163
Buy
|
1.9876
Buy
|
| MA50 |
1.968
Buy
|
1.9682
Buy
|
| MA100 |
1.9944
Buy
|
1.9815
Buy
|
| MA200 |
1.9402
Buy
|
2.0377
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, IPHA could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 0 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on IPHA, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 63.5 indicates that IPHA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 53.38 indicates that IPHA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 79.71 indicates that IPHA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 40.68 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 66.71 indicates that IPHA is still overbought but not to an extreme extent.
Long-term IPHA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Innate Pharma Adr financial reports and earnings history, Innate Pharma Adr (IPHA) stock could reach $1.0468 by 2030, $6.3489 by 2040 and $15.39 by 2050. See the projected annual prices until 2050 of the Innate Pharma Adr stock below:
- Innate Pharma Adr (IPHA) is expected to reach an average price of $6.2929 in 2035, with a high prediction of $5.4629 and a low estimate of $3.1174. This indicates an $192.69% rise from the last recorded price of $2.15.
- Innate Pharma Adr (IPHA) stock is projected to chart a bullish course in 2040, with an average price target of $6.6159, representing an $207.72% surge from its current level. The forecast ranges from a conservative $6.6159 to a sky-high $6.3489.
- Our analysts predict Innate Pharma Adr (IPHA) to jump 444.91% by 2045, soaring from $11.63 to an average price of $11.72, potentially reaching $11.47. While $11.63 is the low estimate, the potential upside is significant.
- Innate Pharma Adr (IPHA) stock is expected to climb by 2050, reaching an average of $15.56, a $623.51% jump from its current level. However, a wide range of estimates exists, with high and low targets of $15.39 and $5.1756, respectively, highlighting the market's uncertainty.
Innate Pharma Adr Stock (IPHA) Year by Year Forecast
Innate Pharma Adr Stock (IPHA) Price Forecast for 2025
Innate Pharma Adr Stock (IPHA) is expected to reach an average price of $2.6405 in 2025, with a high prediction of $4.8978 and a low estimate of $0.3832. This indicates an +22.81% rise from the last recorded price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| September, 2025 | $1.6171 | $0.9834 | $1.9171 | -24.79% |
| October, 2025 | $1.3764 | $0.9907 | $1.9278 | -35.98% |
| November, 2025 | $1.608 | $1.2522 | $1.738 | -25.21% |
| December, 2025 | $1.4773 | $0.9995 | $1.8358 | -31.29% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2026
The predicted value for Innate Pharma Adr (IPHA) in 2026 is set at an average of $4.7238. Estimates vary from a peak of $9.2164 to a trough of $0.2312, indicating an +119.71% surge from the present price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.125 | $0.921 | $1.4658 | -47.67% |
| February, 2026 | $1.2803 | $0.7425 | $1.4503 | -40.45% |
| March, 2026 | $0.6918 | $0.414 | $1.3682 | -67.82% |
| April, 2026 | $0.5209 | $0.2312 | $0.7432 | -75.77% |
| May, 2026 | $0.8827 | $0.4011 | $0.9427 | -58.94% |
| June, 2026 | $3.9742 | $0.8706 | $9.2164 | +84.85% |
| July, 2026 | $2.8936 | $2.8236 | $4.4821 | +34.59% |
| August, 2026 | $2.3551 | $2.2951 | $3.3693 | +9.54% |
| September, 2026 | $2.6645 | $1.6387 | $2.7645 | +23.93% |
| October, 2026 | $1.946 | $1.8202 | $2.7402 | -9.49% |
| November, 2026 | $1.2675 | $0.8719 | $1.9439 | -41.05% |
| December, 2026 | $0.3169 | $0.3169 | $1.3054 | -85.26% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Innate Pharma Adr (IPHA) is $0.9389, with a high forecast of $1.8664 and a low forecast of $0.0113. This indicates an -56.33% decrease from the last price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.8784 | $0.1548 | $1.0584 | -59.15% |
| February, 2027 | $0.6199 | $0.5029 | $1.0763 | -71.17% |
| March, 2027 | $0.6293 | $0.2178 | $0.7714 | -70.73% |
| April, 2027 | $0.3792 | $0.2571 | $0.7789 | -82.36% |
| May, 2027 | $0.5623 | $0.1386 | $0.6344 | -73.85% |
| June, 2027 | $0.5917 | $0.3051 | $0.8758 | -72.48% |
| July, 2027 | $0.3732 | $0.3232 | $0.8595 | -82.64% |
| August, 2027 | $0.2453 | $0.0268 | $0.9068 | -88.59% |
| September, 2027 | $0.056 | $0.106 | $0.0896 | -97.40% |
| October, 2027 | $0.0455 | $0.0162 | $0.3477 | -97.88% |
| November, 2027 | $0.243 | $0.0113 | $0.247 | -88.70% |
| December, 2027 | $1.4664 | $0.2249 | $1.8664 | -31.79% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2028
In 2028, Innate Pharma Adr (IPHA) is projected to reach an average price of $0.8904, with a high projection of $1.7043 and a low estimate of $0.0766. This indicates an -58.58% fall from the last price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.2479 | $1.1434 | $1.7043 | -41.96% |
| February, 2028 | $0.7694 | $0.3516 | $1.4494 | -64.21% |
| March, 2028 | $1.1638 | $0.4831 | $1.3888 | -45.87% |
| April, 2028 | $1.0303 | $0.7503 | $1.3967 | -52.08% |
| May, 2028 | $0.9997 | $0.8282 | $1.0982 | -53.50% |
| June, 2028 | $1.1762 | $1.0126 | $1.6554 | -45.29% |
| July, 2028 | $1.1694 | $1.0091 | $1.4148 | -45.61% |
| August, 2028 | $0.9221 | $0.8321 | $1.1963 | -57.11% |
| September, 2028 | $1.1736 | $0.885 | $1.3457 | -45.41% |
| October, 2028 | $0.5501 | $0.3351 | $1.2415 | -74.41% |
| November, 2028 | $0.6445 | $0.0766 | $0.993 | -70.02% |
| December, 2028 | $0.746 | $0.5343 | $0.9381 | -65.30% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2029
The 2029 price forecast for Innate Pharma Adr Stock (IPHA) is $1.0534 on average, with a high prediction of $2.052 and a low estimate of $0.0548. This represents an -51.01% decrease from the previous price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.2654 | $0.5814 | $1.4134 | -41.15% |
| February, 2029 | $1.0569 | $0.8487 | $1.3032 | -50.84% |
| March, 2029 | $1.0684 | $0.7047 | $1.0826 | -50.31% |
| April, 2029 | $0.9649 | $0.7562 | $1.132 | -55.12% |
| May, 2029 | $0.9192 | $0.6979 | $1.6214 | -57.24% |
| June, 2029 | $1.06 | $0.7551 | $1.0729 | -50.70% |
| July, 2029 | $0.827 | $1.137 | $1.1027 | -61.54% |
| August, 2029 | $1.1282 | $1.024 | $0.8155 | -47.52% |
| September, 2029 | $0.1748 | $0.0548 | $1.2448 | -91.87% |
| October, 2029 | $0.7235 | $0.1237 | $0.842 | -66.35% |
| November, 2029 | $0.2265 | $0.2265 | $1.0708 | -89.46% |
| December, 2029 | $0.1105 | $0.8305 | $2.052 | -94.86% |
Innate Pharma Adr Stock (IPHA) Price Forecast for 2030
Innate Pharma Adr Stock (IPHA) is expected to reach an average price of $1.2319 in 2030, with a high forecast of $2.3721 and a low forecast of $0.0917. This signifies an -42.70% decrease from the last price of $2.15.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.8883 | $0.0917 | $1.0468 | -58.68% |
| February, 2030 | $0.6287 | $0.2544 | $1.5656 | -70.76% |
| March, 2030 | $0.1357 | $0.5157 | $0.1357 | -93.69% |
| April, 2030 | $0.4427 | $0.4384 | $0.9458 | -79.41% |
| May, 2030 | $0.1939 | $0.1312 | $0.2588 | -90.98% |
| June, 2030 | $0.3019 | $0.1867 | $0.2218 | -85.96% |
| July, 2030 | $2.3921 | $2.4521 | $2.3721 | +11.26% |
| August, 2030 | $1.8491 | $2.3749 | $2.0606 | -13.99% |
| September, 2030 | $0.6161 | $1.1857 | $1.8334 | -71.34% |
| October, 2030 | $1.8274 | $0.8204 | $1.6874 | -15.01% |
| November, 2030 | $1.5444 | $1.6301 | $1.6316 | -28.17% |
| December, 2030 | $1.5814 | $1.6171 | $1.5486 | -26.45% |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):